- Trial Phase
- Early/IND-stage (proof-of-concept trial planned); program under full FDA clinical hold — effectively stalled
- Time to Market
- Unknown — likely many years away. The program is early proof-of-concept (only preclinical data published) and the IND is fully on clinical hold, so no trials are actively advancing; commercialization is not realistically estimable.
- Why 3/10
- No hard, dated binary exists in the next ~12 months: the only event that could move FLNA materially is FDA lifting the full clinical hold on simufilam's TSC-epilepsy IND (in place since Dec 2025, no resolution timeline per the May 7 and July 29, 2026 filings), so impact stays low (3) despite simufilam being essentially the company's entire value — proximity is unknown, concentration is total.
The single thing to watch is FDA feedback on the clinical hold — that is the only catalyst that can materially reprice this stock (it fell ~10% on the May 2026 hold disclosure; a lift would be explosive given ~12.9% short interest vs. estimated shares outstanding). Also track cash: $82.7M at June 30, 2026, guided to just $36–40M unrestricted by year-end 2026 after the $31.25M litigation settlement went into escrow. Analyst price targets (mean $6.50 vs. ~$1.01 price) assume a successful restart; treat them as optionality, not a near-term base case.
Price Chart
Executive Summary
Simufilam is the sole pipeline asset of Filana Therapeutics (FLNA), a micro-cap biotech that rebranded from Cassava Sciences in March 2026 after abandoning Alzheimer's and pivoting to TSC-related epilepsy (~45,000 U.S. patients). The drug is promising only at the preclinical stage (mouse-model data in Epilepsia), and its clinical path is blocked: FDA placed a full clinical hold on the IND in December 2025, still unresolved as of the July 29, 2026 Q2 report. Financially, the company has no revenue, an $82.7M cash balance burning ~$12.7M per half-year, and a $31.25M litigation settlement already paid into escrow. Net investor read is bearish near-term: an undated regulatory overhang on the only asset, near the 52-week low, with bearish positioning signals — though the stock retains speculative optionality if the hold is ever lifted.
How It Works
Simufilam is an oral small-molecule pill that modulates a structural protein called filamin A, which helps cells (including brain cells) keep their shape and transmit signals. The company's current theory: in tuberous sclerosis complex (TSC), abnormal filamin A signaling contributes to seizures, and modulating it may slow seizure progression. The same molecule was previously studied as an Alzheimer's disease treatment before that program was wound down.
Trial Status
FDA imposed a full clinical hold on the simufilam IND for TSC-related epilepsy in December 2025; it was still active per the May 7, 2026 Q1 report and the July 29, 2026 Q2 report, with the company "engaging with FDA" and no resolution timeline. Only preclinical data exist: an April 15, 2026 publication in Epilepsia showed simufilam attenuated seizure progression in a mouse model of severe TSC-related epilepsy. The prior Alzheimer's disease program was phased out (per Q1 2026 reporting). No active Phase 2/3 industry-sponsored trials were found in the local ClinicalTrials.gov records.
The Two-Sided Case
Upcoming Catalysts
- FDA feedback on / resolution of the full clinical hold on simufilam's TSC-epilepsy IND — undated, but the single most important event to monitor
- Q3 2026 earnings release (Q2 2026 was reported July 29, 2026; the earnings calendar lists FLNA Q2 2026 on Aug 5, 2026 with an EPS estimate of -$0.357)
- Court approval of the $31.25M litigation settlement already placed in escrow
- Any new simufilam preclinical or clinical disclosure (e.g., follow-on data after the April 2026 Epilepsia publication)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
FILANA THERAPEUTICS, INC. 8-K FLNA ·Originating report